• Filter By:
• Specialty
• Source
• Condition
• Cancer
• Infectious Disease
• Drug
• Training
• Management
• Procedure
• Therapy
• Vaccine
• Nutrition
• Country

Patient Characteristics and Risk of Bleeding With Dabigatran
To the Editor We appreciate the interesting study by Hernandez et al on the risk of bleeding with dabigatran in patients with atrial fibrillation. These are important data to an ongoing controversy. However, we would appreciate an author comment regarding the external validity of the study. To what extent is this sample of Medicare beneficiaries representative of the general population of patients with atrial fibrillation? Comparing the characteristics of patients in the RE-LY Study and the Danish population-based study, it seems that these are not effortlessly comparable. In the study by Hernandez et al, patients are cons...
Source: JAMA Internal Medicine - July 1, 2015 Category: Internal Medicine Source Type: research

Dabigatran etexilate as second-line therapy in patients with a left ventricular assist device.
CONCLUSIONS: The safe and effective use of dabigatran as a second-line anticoagulation therapy in patients with HMII seems feasible. However, these data must be confirmed in a randomized study. PMID: 25701968 [PubMed - in process]
Source: Hellenic Journal of Cardiology - November 18, 2015 Category: Cardiology Tags: Hellenic J Cardiol Source Type: research

Trends in the prescription of novel oral anticoagulants in UK primary care
ConclusionsIn the UK, the initiation of NOAC has increased substantially since 2009, and NOAC have now surpassed VKA as the anticoagulant of choice. Moreover, the characteristics of patients initiated on NOAC have changed over time, and this should be accounted for in future studies comparing NOAC and VKA.
Source: British Journal of Clinical Pharmacology - April 1, 2017 Category: Drugs & Pharmacology Authors: S. Y. Loo, S. Dell'Aniello, L. Huiart, C. Renoux Tags: PHARMACOEPIDEMIOLOGY Source Type: research

Efficacy and Safety of Direct Oral Anticoagulants in Patients With Atrial Fibrillation and High Thromboembolic Risk. A Systematic Review
Conclusions: The use of DOACs is a reasonable alternative to vitamin K antagonists in AF patients with CHADS2 score ≥3, advanced age, and HF. The RI constitutes a useful, additional tool to facilitate clinicians in choosing DOACs or warfarin in particular category of AF patients.
Source: Frontiers in Pharmacology - September 18, 2019 Category: Drugs & Pharmacology Source Type: research

Pages: 1  2  3  4  5  6